These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9159328)

  • 1. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
    Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM; Werness BA; Mark HF
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
    Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
    Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
    J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
    Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
    Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
    Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.
    Al-Moundhri MS; Nirmala V; Al-Hadabi I; Al-Mawaly K; Burney I; Al-Nabhani M; Thomas V; Ganguly SS; Grant C
    J Surg Oncol; 2005 Sep; 91(4):243-52. PubMed ID: 16121348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
    Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
    Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
    Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
    Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
    Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
    Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
    Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
    J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
    Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
    Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.